GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Price-to-Owner-Earnings

ProQR Therapeutics NV (ProQR Therapeutics NV) Price-to-Owner-Earnings : 6.63 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Price-to-Owner-Earnings?

As of today (2024-04-29), ProQR Therapeutics NV's share price is $1.9899. ProQR Therapeutics NV's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.30. It's Price-to-Owner-Earnings for today is 6.63.


The historical rank and industry rank for ProQR Therapeutics NV's Price-to-Owner-Earnings or its related term are showing as below:

PRQR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.58   Med: 7.92   Max: 23.12
Current: 6.75

During the past 12 years, the highest Price-to-Owner-Earnings of ProQR Therapeutics NV was 23.12. The lowest was 6.58. And the median was 7.92.


PRQR's Price-to-Owner-Earnings is ranked better than
90.53% of 169 companies
in the Biotechnology industry
Industry Median: 32.12 vs PRQR: 6.75

As of today (2024-04-29), ProQR Therapeutics NV's share price is $1.9899. ProQR Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.38. Therefore, ProQR Therapeutics NV's PE Ratio for today is At Loss.

As of today (2024-04-29), ProQR Therapeutics NV's share price is $1.9899. ProQR Therapeutics NV's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.43. Therefore, ProQR Therapeutics NV's PE Ratio without NRI for today is At Loss.


ProQR Therapeutics NV Price-to-Owner-Earnings Historical Data

The historical data trend for ProQR Therapeutics NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Price-to-Owner-Earnings Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 6.71

ProQR Therapeutics NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 13.98 6.71

Competitive Comparison of ProQR Therapeutics NV's Price-to-Owner-Earnings

For the Biotechnology subindustry, ProQR Therapeutics NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Price-to-Owner-Earnings falls into.



ProQR Therapeutics NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ProQR Therapeutics NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.9899/0.30
=6.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProQR Therapeutics NV  (NAS:PRQR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ProQR Therapeutics NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.